Gene therapy for Parkinson's disease: where are we now and where are we going?
about
Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryLong-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's diseaseTesting the contributions of striatal dopamine loss to the genesis of parkinsonian signsGene therapy for misfolding protein diseases of the central nervous system.
P2860
Gene therapy for Parkinson's disease: where are we now and where are we going?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Gene therapy for Parkinson's disease: where are we now and where are we going?
@en
Gene therapy for Parkinson's disease: where are we now and where are we going?
@nl
type
label
Gene therapy for Parkinson's disease: where are we now and where are we going?
@en
Gene therapy for Parkinson's disease: where are we now and where are we going?
@nl
prefLabel
Gene therapy for Parkinson's disease: where are we now and where are we going?
@en
Gene therapy for Parkinson's disease: where are we now and where are we going?
@nl
P2093
P2860
P356
P1476
Gene therapy for Parkinson's disease: where are we now and where are we going?
@en
P2093
John Forsayeth
Krystof S Bankiewicz
Michael J Aminoff
P2860
P304
P356
10.1586/ERN.10.161
P577
2010-12-01T00:00:00Z